Next Article in Journal
Afatinib in Advanced Pretreated Non-Small-Cell Lung Cancer—A Canadian Experience
Previous Article in Journal
Exploring Cancer Centres for Physical Activity and Sedentary Behaviour Support for Breast Cancer Survivors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 5
10.3747/co.25.3840
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges

by
N. A. Nixon
1,
N. Blais
2,
S. Ernst
3,
C. Kollmannsberger
4,
G. Bebb
1,
M. Butler
5,
M. Smylie
6 and
S. Verma
1,*
1
Tom Baker Cancer Centre, Calgary, AB, Canada
2
chum–Hôpital Notre-Dame, Montreal, QC, Canada
3
London Health Sciences Centre, London, ON, Canada
4
BC Cancer, Vancouver, BC, Canada
5
University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
6
Cross Cancer Institute, Edmonton, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(5), 373-384; https://doi.org/10.3747/co.25.3840
Submission received: 1 October 2018 / Revised: 1 October 2018 / Accepted: 1 October 2018 / Published: 1 October 2018

Abstract

Immunotherapy has emerged as a new standard of care, showing survival benefit for solid tumours in multiple disease sites and indications. The survival improvements seen in diseases that were highly resistant to traditional therapies, with a poor prognosis, are unprecedented. Although the benefits observed in clinical trials are undeniable, not all patients derive those benefits, leading to emerging combination strategies and an ongoing quest for biomarker selection. Here, we summarize the current evidence for immunotherapy in the treatment of solid tumours, and we discuss emerging strategies at the forefront of research. We discuss future challenges that will be encountered as experience and knowledge continue to expand in this rapidly emerging field.
Keywords: immuno-oncology immuno-oncology

Share and Cite

MDPI and ACS Style

Nixon, N.A.; Blais, N.; Ernst, S.; Kollmannsberger, C.; Bebb, G.; Butler, M.; Smylie, M.; Verma, S. Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. Curr. Oncol. 2018, 25, 373-384. https://doi.org/10.3747/co.25.3840

AMA Style

Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, Smylie M, Verma S. Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. Current Oncology. 2018; 25(5):373-384. https://doi.org/10.3747/co.25.3840

Chicago/Turabian Style

Nixon, N. A., N. Blais, S. Ernst, C. Kollmannsberger, G. Bebb, M. Butler, M. Smylie, and S. Verma. 2018. "Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges" Current Oncology 25, no. 5: 373-384. https://doi.org/10.3747/co.25.3840

APA Style

Nixon, N. A., Blais, N., Ernst, S., Kollmannsberger, C., Bebb, G., Butler, M., Smylie, M., & Verma, S. (2018). Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. Current Oncology, 25(5), 373-384. https://doi.org/10.3747/co.25.3840

Article Metrics

Back to TopTop